These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 28005225

  • 21. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S, Katterle Y, Beckmann H, Maas Enriquez M.
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
    Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY, Prophylaxis Study Group.
    J Thromb Haemost; 2012 Mar; 10(3):359-67. PubMed ID: 22212248
    [Abstract] [Full Text] [Related]

  • 24. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S, Núñez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S.
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, Maas Enriquez M.
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A.
    Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E.
    J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
    [Abstract] [Full Text] [Related]

  • 33. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P, Fischer K, Collins PW, Cotterill A, Konkle BA, Blanchette V, Pipe SW, Berntorp E, Wolfsegger M, Engl W, Spotts G.
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [Abstract] [Full Text] [Related]

  • 34. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
    Solms A, Iorio A, Ahsman MJ, Vis P, Shah A, Berntorp E, Garmann D.
    Clin Pharmacokinet; 2020 May; 59(5):605-616. PubMed ID: 31749076
    [Abstract] [Full Text] [Related]

  • 35. Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
    Berntorp E, Spotts G, Patrone L, Ewenstein BM.
    Biologics; 2014 May; 8():115-27. PubMed ID: 24741292
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L.
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [Abstract] [Full Text] [Related]

  • 37. Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
    Shafer F, Charnigo RJ, Plotka A, Baumann J, Liang Y, Korth-Bradley J.
    Clin Pharmacol Drug Dev; 2015 Jan; 4(3):237-41. PubMed ID: 27140804
    [Abstract] [Full Text] [Related]

  • 38. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
    Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M, LEOPOLD II Study Investigators.
    J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
    [Abstract] [Full Text] [Related]

  • 39. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.
    Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA.
    Haemophilia; 2017 Jul; 23(4):528-537. PubMed ID: 28220555
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.